Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINERVA: Prolonged-Release Pirfenidone in HCV Patients with Advanced Fibrosis
NCT05542615Phase 2Unknown
- Sponsor
- Universidad de Guadalajara
- Start
- Aug 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pirfenidone in Liver Fibrosis (LF), sponsored by Universidad de Guadalajara. Primary endpoints: Reduction of fibrosis via liver biopsy at 12 months and Liver Elastography at 12 months. Status: unknown.
02
Drugs
pirfenidone
03
Conditions
Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT05542615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05542615.